Vicapsys Life Sciences, Inc. (OTCMKTS:VICP – Get Free Report) was down 78.6% during trading on Monday . The company traded as low as $1.50 and last traded at $1.50. Approximately 207 shares were traded during trading, a decline of 76% from the average daily volume of 874 shares. The stock had previously closed at $7.00.
Vicapsys Life Sciences Price Performance
The firm has a fifty day simple moving average of $1.51 and a 200 day simple moving average of $1.84. The company has a market cap of $48.11 million, a price-to-earnings ratio of -50.00 and a beta of -4.14.
Vicapsys Life Sciences (OTCMKTS:VICP – Get Free Report) last issued its quarterly earnings results on Monday, October 21st. The company reported ($0.01) EPS for the quarter.
Vicapsys Life Sciences Company Profile
Vicapsys Life Sciences, Inc focuses on the development and commercialization of VICAPSYN, a proprietary product. The company’s product is applied to transplantation therapies and related stem-cell applications in the transplantation field. It also develops VYBRIN, a product based on CXCL12 for prevention of post-surgical adhesions in abdominal surgery, coating of implantable medical devices and other implants to eliminate fibrosis, and wound healing with a focus on diabetic ulcers.
Featured Articles
- Five stocks we like better than Vicapsys Life Sciences
- There Are Different Types of Stock To Invest In
- 2 Stocks to Gain From Trump Universal Tariffs on Critical Imports
- How to buy stock: A step-by-step guide for beginners
- Rigetti Computing, Inc.: Buy, Sell, or Hold for 2025
- What is a Secondary Public Offering? What Investors Need to Know
- Delta Can Fly to New Highs in 2025; Here’s Why
Receive News & Ratings for Vicapsys Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vicapsys Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
